San Francisco, United States
EV Therapeutics, with its slogan "Immunotherapy EVolved," is at the forefront of developing innovative treatments targeting advanced stage metastatic colorectal cancers. Founded in 2020 and headquartered in the United States, the company operates within the Biotechnology and Health Care industries.
The company's unique value proposition lies in its proprietary technology involving modified extracellular vesicles (mEVs). These mEVs offer a dual-action approach: they enhance tumor antigen-specific T cell infiltration and synergize with immune checkpoint blockade therapies, potentially offering significant survival benefits. Pre-clinical data indicate promising outcomes, particularly in controlling minimal residual disease and preventing cancer recurrence, positioning the therapy also as a cancer vaccine.
EV Therapeutics is currently exploring opportunities for out-licensing, co-development, and partnerships, making it an appealing target for strategic collaborations and investment.
